Onconetix Stock Soars 13.21% on New Clinical Data

Onconetix's stock price surged by 13.21% in pre-market trading on March 27, 2025, marking a significant rise that has caught the attention of investors and analysts alike.

Onconetix, Inc. has been facing several negative signals and is currently within a very wide and falling trend. This has led analysts to believe that the stock may continue to perform weakly in the near future. The company's stock exhibits significant volatility compared to the market, with a beta of 3.27, indicating that it is more sensitive to market movements than the average stock.

Despite the recent volatility, Onconetix has announced new clinical data for its products, which could potentially impact its stock price in the coming days. Investors are advised to be aware of the risks associated with investing in the futures and options markets, as well as the financial risks involved in trading on margin.